RxDoctor Payments Data

Keith Dietrick, MD

Interventional Pain Medicine · Wellington, FLNPI 1144223785

Payments from drug & device makers

$2,633in general payments, 2019–2025

Across 191 payments — averaging $13.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$810
  • Collegium Pharmaceutical, Inc.$749
  • Nevro Corp.$187
  • Biodelivery Sciences International, Inc.$156
  • Scilex Pharmaceuticals Inc.$151
  • Abbott$133
  • plus $447 from 15 others

What the payments were for

  • Food & beverage$2,633100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen84$810
Collegium Pharmaceutical, Inc.55$749
Nevro Corp.5$187
Biodelivery Sciences International, Inc.9$156
Scilex Pharmaceuticals Inc.8$151
Abbott7$133
Kowa Pharmaceuticals America, Inc.3$55
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC3$51
Pfizer3$48
IBSA Pharma Inc.2$43
Medtronic(2 entities)2$39
Boston Scientific1$34
Protega Pharmaceutials Inc1$32
AbbVie1$27
Novartis1$22
Pernix Therapeutics Holdings, Inc.1$18
Forte Bio-pharma LLC1$17
Valinor Pharma, LLC1$17
GRT US Holding, Inc.1$17
Vertos Medical, Inc.1$14
Sentynl Therapeutics, Inc.1$12

How this compares

$2,633 in reported general payments places this provider in the 35th percentile of 278 interventional pain medicine providers in Florida.

See all interventional pain medicine providers in Florida

Medicare billing

Part B allowed, 2024
$381,640
Medicare patients
410
Services billed
4,297

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate166$104,873
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen2,118$68,402
OxycontinOxycodone Hcl65$61,031
Fentanyl198$28,119
MovantikNaloxegol Oxalate54$23,386
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,137$18,060
Morphine Sulfate ErMorphine Sulfate504$16,440
LinzessLinaclotide23$12,205
Gabapentin888$8,209
Lidocaine85$8,178
Tramadol Hcl839$7,094
Oxycodone Hcl357$4,357
BelbucaBuprenorphine Hcl11$4,171
Buprenorphine25$3,990
ButransBuprenorphine11$3,333

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$749$109,044177 claims
AbbVieLinzess$27$12,20523 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 278 interventional pain medicine providers in Florida.

Other interventional pain medicine in Wellington

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →